Literature DB >> 19664077

Palliative radiation therapy practice for advanced esophageal carcinoma in Africa.

V Sharma1, P M Gaye, S A Wahab, N Ndlovu, T Ngoma, V Vanderpuye, A Sowuhami, D A Dawotola, J Kigula-Mugambe, B Jeremic.   

Abstract

While numerous surveys of pattern of practices of palliative radiotherapy (RT) in advanced esophageal cancers have been published in developed countries, there is no such survey in African countries. During and after a regional training course by the International Atomic Energy Agency (IAEA) in palliative cancer care, a questionnaire was distributed to African RT centers to gather information about infrastructure and human resources available, and the pattern of practice of palliative RT for esophageal cancers. Twenty-four of the 35 centers (60%) completed the questionnaire. Twenty out of 23 (87%) centers treat patients with esophageal cancer presenting with dysphagia using external beam RT (16 centers external beam RT alone and 4 centers also use brachytherapy as a boost). Twelve (60%) centers prescribe RT doses of 30 Gy in 10 fractions and 2 centers 20 Gy in 5 fractions. Eighteen centers (78%) have low dose rate (LDR) brachytherapy, and 9 (39%) centers have high dose rate (HDR) brachytherapy. One center only used HDR brachytherapy alone to a dose of 16 Gy in 2 fractions over 8 days. RT remains a major component of treatment of patients with esophageal cancers in African countries. Still, there is a great variety among centers in both indications for RT and its characteristics for a treatment indication.

Entities:  

Mesh:

Year:  2009        PMID: 19664077     DOI: 10.1111/j.1442-2050.2009.00997.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  1 in total

1.  Definition of fields margins for palliative radiotherapy of pancreatic carcinoma.

Authors:  Milly Buwenge; Alfonso Marinelli; Francesco Deodato; Gabriella Macchia; Tigeneh Wondemagegnhu; Tareq Salah; Silvia Cammelli; A F M Kamal Uddin; Mostafa A Sumon; Constanza M Donati; Savino Cilla; Alessio G Morganti
Journal:  Mol Clin Oncol       Date:  2018-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.